Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients With Non-CNS Met Fusion Solid Tumors From Its Phase 2 Sparta Trial
阿波洛米克宣佈其2期Sparta試驗中Vebreltinib在非中樞神經系統MET融合實體瘤患者中取得積極的初步數據
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients With Non-CNS Met Fusion Solid Tumors From Its Phase 2 Sparta Trial
阿波洛米克宣佈其2期Sparta試驗中Vebreltinib在非中樞神經系統MET融合實體瘤患者中取得積極的初步數據
譯文內容由第三人軟體翻譯。